Lymphoma
Conditions
Keywords
18 FDG PET CT, Lymphoma
Brief summary
1. To assess staging accuracy of F-18 FDG PET/CT in lymphoma 2. Determine the role of F-18 FDG PET/CT in monitoring treatment response and detecting relapse or residual disease in lymphoma 3. To evaluate FDG uptake correlation with histopathological subtypes and immunophenotypes as a prognostic factor.
Detailed description
The incidence of lymphoma in Egypt has been increasing in recent years, with a noticeable rise in both Hodgkin's and non-Hodgkin's lymphoma cases. This increase is due to better healthcare, awareness, and diagnostic advancements. Risk factors include infections, lifestyle, genetics, and immune system issues. Lymphoma is now the fourth most prevalent cancer among Egyptian adults, accounting for approximately 8.4% of all new cancer cases annually. As the burden of lymphoma grows, it becomes essential to develop effective strategies for its diagnosis and management. Flurodeoxyglucose F-18 (F-18 FDG) is a radiolabeled glucose analog that accumulates in metabolically active cells, such as lymphoma cells, making F-18 FDG positron emission tomography / computed tomography scan (PET/CT) highly sensitive for detecting malignant lesions. It plays a key role in staging lymphoma by assessing the extent of disease spread. Additionally, F-18 FDG PET/CT is essential for assessing treatment response, detecting relapses early, and evaluating the prognosis of patients, offering prognostic value by evaluating residual disease and predicting recurrence. Its ability to monitor disease progression and detect recurrent lymphoma provides critical insights that guide therapeutic decisions and long-term outcomes.
Interventions
DEVICE18 FDG
18 flurodeoxy glucose PET/CT
Sponsors
Assiut University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age: Patient must be older than 18 years. * Confirmed Diagnosis of Lymphoma: Patient must have a confirmed diagnosis of lymphoma based on histopathology and immunophenotyping.
Exclusion criteria
* Patients with Known concomitant malignancy. * Pregnancy: Pregnant women due to the potential risks associated with radiation exposure from the PET/CT scan. * Severe Renal or Hepatic Impairment: Patients with significant renal or hepatic dysfunction that could affect FDG metabolism or excretion. * Uncontrolled Diabetes: Patients with uncontrolled diabetes (blood glucose \>200 mg/dL), as it can affect FDG uptake and PET/CT results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| primary | 3 years | Treatment Response Using Deauville Score for FDG Uptake Evaluation: Evaluate FDG uptake using the 5-point scale: 1. No uptake above background 2. Uptake ≤ mediastinum 3. Uptake \> mediastinum but ≤ liver 4. Moderately increased compared to liver 5. Markedly increased compared to liver X: New uptake, unlikely related to lymphoma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| secondary | 3 years | Detect early relapse or residual disease using F-18 FDG PET/CT using SUVmax, maximum standardized uptake value(g/mL ) |
Countries
Egypt
Contacts
Primary ContactAya A Ahmed Ali ALsanory, MSc
Backup ContactMohamed A Mekkawy, Prof
Outcome results
None listed